Why is Titan Biotech falling/rising?

As of 09-Jul, Titan Biotech Ltd's stock price is currently at 456.00, reflecting a decrease of 2.0, or 0.44%. The stock has underperformed its sector by 0.42% today, and while it is above its 5-day, 20-day, and 50-day moving averages, it remains below its 100-day and 200-day moving averages. Over the past week, the stock has shown a positive return of 11.08%, but it has significantly underperformed over the year with a decline of 24.00%. The company has reported negative results for the last three consecutive quarters, with a notable drop in profit before tax and a decrease in profit after tax. Despite having a high return on equity of 25.08% and a low debt-to-equity ratio, the overall sentiment remains cautious due to poor long-term growth indicators and declining investor participation, as evidenced by a 70.64% drop in delivery volume.
In the broader market context, the Sensex has only increased by 0.15% over the past week, indicating that Titan Biotech's short-term performance is significantly stronger than the benchmark. However, the stock's year-to-date performance is concerning, with a decline of 37.77% compared to the Sensex's gain of 6.91%. This stark contrast highlights the challenges Titan Biotech faces in regaining investor confidence, particularly given its recent financial struggles and the fact that it has underperformed the market over the last year. The combination of high valuations relative to peers and declining profitability further complicates the outlook for the stock.